Senseonics Receives FDA Approval to Combine CGM Implants with Insulin Pumps.

The Eversense CGM implant from Senseonics eliminates the need for fingerstick blood glucose testing. The existing gadget continuously detects blood sugar levels lasting as long as 180 days, but beyond day 21 and when indicators differ from the CGM it needs to be calibrated every day using a fingerstick. In the CGM market, Abbott and Dexcom are the leading sellers of short-term solutions.  

Eversense can interface with healthcare technology that is a match, including pumps for insulin, thanks to the iCGM classification. With regard to connections, Senseonics intends to move forward with discussions with pump producers on the implementation of its implant in devices that modify the administration of insulin in response to CGM data. 

Will make Eversense more appealing to the larger segment of the population due to its broader integration potential,” BTIG analysts wrote in a letter to investors. “However, we have yet to see consistent adoption of Eversense.”